Christopher Richard Anzalone, Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 53,424 shares at $20.52 ($1.1M) on 2024-12-18, disclosed to the SEC on 2024-12-20.
Scheduled sale ($1.1M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.52 | 12,653 | $260K | 22.9% |
| 2 | $20.52 | 12,653 | $260K | 22.9% |
| 3 | $21.74 | 8,260 | $180K | 15.8% |
| 4 | $21.74 | 8,260 | $180K | 15.8% |
| 5 | $22.12 | 5,799 | $128K | 11.3% |
| 6 | $22.12 | 5,799 |
| $128K |
| 11.3% |
| Total | $21.24 avg | 53,424 | $1.1M | 100% |
| Filing → |
| ARWR | SELL | 2025-12-23 | $3.5M | — | Filing → |
| ARWR | SELL | 2025-12-19 | $10.9M | — | Filing → |
| ARWR | SELL | 2025-12-16 | $24.6M | — | Filing → |